INIngemar Nilsson

Ingemar Nilsson

*This is an algorithmically generated author record based on publicly available information.

Ingemar Nilsson has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Beyond the Scope of Free-Wilson Analysis. 2: Can Distance Encoded R-Group Fingerprints Provide Interpretable Nonlinear Models?

    by Mats Eriksson, Hongming Chen, Lars Carlsson, J. Willem M. Nissink, John G. Cumming, Ingemar Nilsson

    In a recent study, we presented a novel quantitative-structure–activity-relationship (QSAR) approach, combining R-group signatures and nonlinear support-vector-machines (SVM), to build interpretable local models for congeneric compound sets. Here, we outline further refinements in the fingerprint scheme for the purpose of analyzing and visualizing structure–activity relationships (SAR). The concept of distance encoded R-group signature descriptors is introduced, and we explore the influence of different signature encoding schemes on both interpretability and predictive power of the SVM models using ten public data sets. The R-group and atomic gradients provide a way to interpret SVM models and enable detailed analysis of structure–activity relationships within substituent groups. We discuss applications of the method and show how it can be used to analyze nonadditive SAR and provide intuitive and powerful SAR visualizations.


  • Beyond the Scope of Free-Wilson Analysis: Building Interpretable QSAR Models with Machine Learning Algorithms

    by Hongming Chen, Lars Carlsson, Mats Eriksson, Peter Varkonyi, Ulf Norinder, Ingemar Nilsson

    A novel methodology was developed to build Free-Wilson like local QSAR models by combining R-group signatures and the SVM algorithm. Unlike Free-Wilson analysis this method is able to make predictions for compounds with R-groups not present in a training set. Eleven public data sets were chosen as test cases for comparing the performance of our new method with several other traditional modeling strategies, including Free-Wilson analysis. Our results show that the R-group signature SVM models achieve better prediction accuracy compared with Free-Wilson analysis in general. Moreover, the predictions of R-group signature models are also comparable to the models using ECFP6 fingerprints and signatures for the whole compound. Most importantly, R-group contributions to the SVM model can be obtained by calculating the gradient for R-group signatures. For most of the studied data sets, a significant correlation with that of a corresponding Free-Wilson analysis is shown. These results suggest that the R-group contribution can be used to interpret bioactivity data and highlight that the R-group signature based SVM modeling method is as interpretable as Free-Wilson analysis. Hence the signature SVM model can be a useful modeling tool for any drug discovery project.


  • Composite multi-parameter ranking of real and virtual compounds for design of MC4R agonists: Renaissance of the Free-Wilson methodology

    by Ingemar Nilsson, Magnus O. Polla

    Drug design is a multi-parameter task present in the analysis of experimental data for synthesized compounds and in the prediction of new compounds with desired properties. This article describes the implementation of a binned scoring and composite ranking scheme for 11 experimental parameters that were identified as key drivers in the MC4R project. The composite ranking scheme was implemented in an AstraZeneca tool for analysis of project data, thereby providing an immediate re-ranking as new experimental data was added. The automated ranking also highlighted compounds overlooked by the project team. The successful implementation of a composite ranking on experimental data led to the development of an equivalent virtual score, which was based on Free-Wilson models of the parameters from the experimental ranking. The individual Free-Wilson models showed good to high predictive power with a correlation coefficient between 0.45 and 0.97 based on the external test set. The virtual ranking adds value to the selection of compounds for synthesis but error propagation must be controlled. The experimental ranking approach adds significant value, is parameter independent and can be tuned and applied to any drug discovery project.


  • Open Access

    SARConnect: A Tool to Interrogate the Connectivity Between Proteins, Chemical Structures and Activity Data

    by Mats Eriksson, Ingemar Nilsson, Thierry Kogej, Christopher Southan, Martin Johansson, Christian Tyrchan, Sorel Muresan, Niklas Blomberg, Marcus Bjäreland

    The access and use of large‐scale structure‐activity relationships (SAR) is increasing as the range of targets and availability of bioactive compound‐to‐protein mappings expands. However, effective exploitation requires merging and normalisation of activity data, mappings to target classifications as well as visual display of chemical structure relationships. This work describes the development of the application “SARConnect” to address these issues. We discuss options for delivery and analysis of large‐scale SAR data together with a set of use‐cases to illustrate the design choices and utility. The main activity sources of ChEMBL,1 GOSTAR2 and AstraZeneca’s internal system IBIS, had already been integrated in Chemistry Connect.3 For target relationships we selected human UniProtKB/Swiss‐Prot4 as our primary source of a heuristic target classification. Similarly, to explore chemical relationships we combined several methods for framework and scaffold analysis into a unified, hierarchical classification where ease of navigation was the primary goal. An application was built on TIBCO Spotfire to retrieve data for visual display. Consequently, users can explore relationships between target, activity and structure across internal, external and commercial sources that encompass approximately 3 million compounds, 2000 human proteins and 10 million activity values. Examples showing the utility of the application are given.


  • From natural products to achiral drug prototypes: Potent thrombin inhibitors based on P2/P3 dihydropyrid-2-one core motifs

    by Stephen Hanessian, Eric Therrien, Jianbin Zhang, Willem van Otterlo, Yafeng Xue, David Gustafsson, Ingemar Nilsson, Ola Fjellström